newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

COAG
  • Hemab Therapeutics presented new clinical data for HMB-002 & announced the HMB-003 program at the ISTH 2026 Congress in Paris.
  • HMB-002 data demonstrated proof of mechanism in Von Willebrand disease (VWD) with dose-dependent increases in Von Willebrand Factor (VWF) & Factor VIII (FVIII) of ≥2.4-fold.
  • HMB-002 treatment resulted in normalization of peak thrombin generation & activated partial thromboplastin time (APTT) with a durability profile supporting potential monthly subcutaneous dosing.
  • HMB-003 is a non-hormonal direct plasmin inhibitor designed to reduce bleeding across multiple settings, starting with heavy menstrual bleeding.
  • HMB-002 utilizes a non-replacement approach by elevating endogenous VWF & FVIII levels rather than infusing exogenous factors.
  • In HMB-002 cohort A3 (150 mg), ≥2.4-fold elevation in both VWF & FVIII was achieved alongside restoration of thrombin generation & stable multimer distribution.
  • HMB-002 showed an emerging safety profile with no serious adverse events, thromboembolic events, injection site reactions, thrombocytopenia, or hypersensitivity reactions.
  • Preliminary clinical observations for HMB-002 indicated that 8 of 9 evaluable patients had zero treated bleeds in the 28 days following dosing.
  • HMB-003 directly inhibits plasmin at its active site to block fibrinolysis while showing no effect on thrombin generation or platelet function in nonclinical studies.
  • Preclinical data for HMB-003 demonstrated sustained antifibrinolytic activity for approximately one week following a single subcutaneous dose in minipigs.
  • HMB-003 is engineered to provide cycle-matched dosing for heavy menstrual bleeding by covering the period & washing out between cycles.
  • Hemab Therapeutics is developing a pipeline including HMB-002 for VWD prophylaxis & HMB-003 for heavy menstrual bleeding, hereditary hemorrhagic telangiectasia, & peri-operative bleeding management.